US · Healthcare · Health Information Services
EPS came in at 0.70 against a street estimate of 0.31 — a beat of 125.8%.
Analysts rate Omnicell Inc a buy (4 buy, 4 hold, 0 sell out of 8) with an average price target of $59.29.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.85% |
| Vanguard Portfolio Management, LLC | 7.07% |
| Wellington Management Company LLP | 5.95% |
| Dimensional Fund Advisors, Inc. | 5.39% |
| Millennium Management LLC | 5.03% |
| State Street Corp | 4.29% |
| Vanguard Capital Management, LLC | 4.25% |
| Lazard Asset Management LLC | 3.23% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-30 |
| Board / officer change · Q2 2026 | 2026-07-01 |
| Board / officer change · Q2 2026 | 2026-05-26 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-04-28 |
| Proxy statement · Q2 2026 | 2026-04-13 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Omnicell Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.